China channel feed – Endpoints News

China channel feed

How about a $477M biotech IPO amid Hong Kong protests? Henlius will find out

6 years ago

Hong Kong strife holds up almost $100M of BioNTech's Series B haul

6 years ago

Private equity meets China biotech: PAG infuses $540M to gain control of Hisun's biosimilar subsidiary

6 years ago

Building on successful PD-1 pact, Eli Lilly licenses diabetes drug to Chinese partners at Innovent

6 years ago

Biotech leaders rally behind Chinese scientists in US, calls for 'measured' policies in wake of purges

6 years ago

China has become a CEO-level priority for multinational pharmaceutical companies: the trend and the implications

6 years ago

Preferential tax policies coming for biopharmas setting up shop in Shanghai's newest free trade zone

6 years ago

Move over, Hong Kong: Shanghai’s new tech board sees fervent demand for maiden biotech IPO

6 years ago

Following footsteps of chart-topping Chinese counterparts, Alphamab Oncology files IPO at HKEX

6 years ago

No clear answers: Yes, recent actions against Chinese American scientists do pose a threat — but maybe those official concerns about espionage are valid too

6 years ago

In a first, HKEX receives IPO pitch from local biotech looking to make it big in crowded antibodies field

6 years ago

Elias Zerhouni: Fear of ‘targeted discrimination’ against Chinese-American scientists threatens an exodus of talent. What do you think?

6 years ago

Trade tensions are impeding the flow of Chinese money to US biotechs — but how much?

6 years ago

Swiss court keeps ex-GSK scientist's brother behind bars as US pushes to extradite him on R&D theft charges

6 years ago

Incyte flips China rights of MacroGenics' PD-1 to an ambitious Zai Lab keen on leapfrogging pioneers with combos

6 years ago

Tasly Biopharma pitches long-awaited IPO — will it trigger another $1B gold rush on HKEX?

6 years ago

Genfit goes to China with a deal worth up to $228M for NASH drug

6 years ago

As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup

6 years ago

Following CAR-T pioneers' footsteps, Tessa launches China JV in $120M deal

6 years ago

Hansoh grabs $1B windfall in the latest China pharma IPO to hit the Hong Kong exchange

6 years ago

Foreign threats to NIH research: Senate Finance Committee digs in

6 years ago

Spreading its wings in China with global ambition, EpimAb snags $74M Series B for bispecific work

6 years ago

Fast moving Chinese regulators wave third homegrown PD-1 to market

6 years ago

Trade war, CFIUS interventions force a shift in strategy at Fosun — signaling some big potential problems for US biotechs

6 years ago

First page Previous page 19 20 212223 24 25 Next page Last page